“Being diagnosed with prostate cancer is not a death knell,” said Montgomery, senior author of a literature and trial review that appeared in JAMA today. Montgomery is the clinical director of ...

Recently, licensed and emerging treatments for metastatic castrate-resistant prostate cancer are transforming the prognosis for men whose disease has already progressed during or after docetaxel ...

Credit: Getty Images Investigators explore the biomarker potential of circulating tumor DNA and tumor suppressor gene status. Elevated circulating tumor DNA fraction and tumor suppressor gene loss ...

Metastatic prostate cancer is cancer that began in the prostate but has spread to other parts of the body. There's no cure, but there are a number of effective treatments you can discuss with a ...

The second most common cancer among men is prostate cancer, affecting 1 in 8 men. Prostate cancer is treatable, in most cases, when the cancer remains localized to the prostate gland. But if the ...

Novartis’ highly-touted radionuclide therapy Pluvicto met its primary endpoint in a phase 3 trial as a second-line therapy for PSMA-positive metastatic castration-resistant prostate cancer ...

Please provide your email address to receive an email when new articles are posted on . TNF inhibitors within 3 years of diagnosis had no statistically significant negative link with colorectal ...